🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

61 results for “nivolumab” Clear

  1. A clinical study to evaluate the efficacy of ceritinib in combination with nivolumab in patients with ALK positive lung cancer

    Novartis Ophthalmics Europe

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  2. BBP-398 with nivolumab

    BridgeBio Oncology Therapeutics

    Non Small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  3. Nivolumab

    United Therapeutics Europe Ltd

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  4. Nivolumab

    Iovance Biotherapeutics B.V.

    Melanoma (Skin)

    phase 1 small molecule completed

    1 trial

  5. Nivolumab

    Atrium Therapeutics

    Brain and Nervous System

    phase 1 small molecule completed

    1 trial

  6. Nivolumab

    China SXT Pharmaceuticals

    Effect of Drug

    phase 1 small molecule active

    1 trial

  7. Nivolumab

    Nektar Therapeutics UK Limited

    Renal Cell Carcinoma

    phase 1 mab completed

    1 trial

  8. Nivolumab

    Iovance Biotherapeutics B.V.

    Non-Small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  9. Nivolumab

    Jazz Pharmaceuticals Ireland Limited

    Small-cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  10. Braftovi 50 mg hard capsules, Zelboraf 240 mg film-coated tablets, Encorafenib, Erbitux 5 mg/mL solution for infusion, PEMBROLIZUMAB, Braftovi 75 mg hard capsules, Braftovi 75 mg hard capsules, Braftovi 50 mg hard capsules, Ribociclib, Ribociclib, NIVOLUMAB, Mektovi 15 mg film-coated tablets, Mektovi 15 mg film-coated tablets, Ribociclib

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Solid tumors

    approved small molecule active

    1 trial

  11. LENVATINIB, NIVOLUMAB, CABOZANTINIB, LENVATINIB, NIVOLUMAB, AXITINIB, CABOZANTINIB, PEMBROLIZUMAB, IPILIMUMAB, AXITINIB, AXITINIB

    Fondazione Telethon ETS

    metastatic or locally advanced renal cell carcinoma

    approved small molecule active

    1 trial

  12. NIVOLUMAB

    Disc Medicine

    Melanoma, Renal cell carcinoma

    approved small molecule active

    1 trial

  13. PEMBROLIZUMAB , NIVOLUMAB , IPILIMUMAB

    Disc Medicine

    Melanoma

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources